3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL(TM) Test for Hodgkin's Lymphoma
3D Signatures Inc. / 3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL(TM) Test for Hodgkin's Lymphoma . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM ) based on the three-dimensional analysis of chromosomal signatures, is pleased to announce the successful and on-time development of the scoring model for Telo-HLTM, the Company's lead test for Hodgkin's lymphoma ("HL"), as well as completion of an analytical validation study to confirm the reproducibility of its Telo-HLTM test.
Powered by the Company's proprietary TeloViewTM platform, Telo-HLTM is a predictive test performed on diagnostic lymph node biopsy specimens, intended to provide clinicians with the first biomarker capable of identifying the 15% - 20% of HL patients who will fail standard ABVD chemotherapy, and who should immediately be considered for more advanced treatment or inclusion into clinical trials with an emerging immunotherapy.
The study data from the Company's multi-parametric telomeric analysis with TeloViewTM was analyzed by an independent statistical provider, BioStat Solutions Inc. ("BSSI"), to develop the Telo-HLTM scoring model from over 200 potential predictors that included different combinations of the telomeric nuclear organization, cell type, and clinical parameters. BSSI identified that a combination of at least three of the parameters analyzed by TeloViewTM contributed to the scoring model with highly predictive characteristics. This included measures unique to 3DS's platform, which can only be evaluated through three-dimensional analysis of telomeres, and for which current clinical data alone is insufficient to predict risk of relapse.
In addition, the Company reports it has successfully run an internal analytical validation of the test by processing and analyzing, in triplicate, archived samples from the same patients. This important step demonstrates the consistency of the Telo-HLTM test and reproducibility of TeloViewTM results under a variety of conditions.
"In keeping with best practices, external scientific peer-review is now essential to confirm our own evaluation of Telo-HLTM's strong performance and reproducibility," notes Dr. Kevin Little, CSO of 3DS. "The detailed findings will be submitted as quickly as possible for presentation in clinician meetings, and then publication in a top-level clinical journal in the latter half of 2018. This will build awareness with key opinion leaders and pharmaceutical companies that Telo-HLTM is ready and available to be incorporated into clinical trials as a correlative biomarker alongside new therapeutic interventions."
"This is the most significant accomplishment for the Company yet, and I congratulate everyone involved for achieving this critical milestone as per our plan," commented Jason Flowerday, CEO of 3DS. "This highly successful study is an important culmination of the work by Dr. Sabine Mai and the 3DS team, to develop the first clinically-compliant and validated test based on telomeric profiling, which can uniquely inform treatment decisions in Hodgkin's lymphoma. Telo-HLTM represents a critical proof-of-principle for the Company's TeloViewTM platform that we believe may establish an entirely new clinical paradigm for genome organization, and accelerate the development of our broader platform of TeloViewTM-based tests in prostate cancer, lung cancer and multiple myeloma."
3DS (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform, TeloView(TM), that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS' TeloView(TM) software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug's efficacy and toxicity. 3DS' proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual's disease based on their unique TeloView ScoreTM. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.
The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer's disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS' intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer's disease.
For more information, visit the Company's website at: http://www.3dsignatures.com.
For further information, please contact:
CEO & Director
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements which constitute "forward-looking information" within the meaning of applicable Canadian securities legislation ("Forward Looking Statements"). All statements included herein, other than statements of historical fact, are Forward-Looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward-Looking Statements. Often, but not always, these Forward-Looking Statements can be identified by the use of words such as "estimates", "potential", "open", "future", "assumes", "projects", "anticipates", "believes", "may", "continues", "expects", "plans", "will", "to be", or statements that events "could" or "should" occur or be achieved, and similar expressions, including negative variations. Statements with respect to 3DS' scoring model for its Telo-HLTM test, validation of TeloViewTM, peer-review and publication of its findings and establishing a new clinical paradigm for genome organization, among others, are Forward-Looking statements.
Such Forward-Looking Statements reflect the Company's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by 3DS as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many risk factors could cause the Company's actual results, performance, achievements, prospects or opportunities to be materially different from any future results, performance or achievements that may be expressed or implied by such Forward-Looking Statements, including risks related to the failure of 3DS' scoring model for its Telo-HLTM test and its analytical validation; the risk that the Telo-HLTM test may not be commercially launched as an LDT or for research use by the first quarter of 2018, or at all; risks that its study results or scoring model may not be peer-reviewed or accepted for publication or presentation; uncertainties related to 3DS' clinical studies and test development; risks related to the volatility of the price of 3DS' common shares; risks related to the possibility that 3DS' shareholders may experience dilution; risks related to 3DS' requirements for additional financing and future access to capital, including the risk that the proceeds raised under the Private Placement may be insufficient to finance 3DS' business objectives; the risk that a positive return on an investment in 3DS' common shares is not guaranteed; risks related to 3DS' intention to retain earnings and not pay cash dividends on its common shares in the foreseeable future; risks related to 3DS' early stage of development; the risk that 3DS' tests will not be successfully deployed; risks related to 3DS' dependence on third parties, including collaborative partners, licensors and others; risks related to 3DS' clinical study recruitment; that there is currently no market for 3DS' products and that such market may be slow to develop if at all; risks related to 3DS' reliance on key personnel; risks related to the competitive nature of the biotechnology industry; risks related to 3DS' limited operating history, lack of revenue, history of losses and inability to assure that it will earn profits in the future or that profitability will be sustained; risks related to government regulation; risks related to rapid technological change; risks related to the fact that 3DS' software may now or in the future contain undetected errors, bugs or vulnerabilities; the risk that 3DS or its directors and officers may be subject to a variety of civil or other legal proceedings, with or without merit, including product liability claims; risks related to the protection of 3DS' intellectual property rights; risks related to 3DS' limited sales, marketing and distribution experience; risks related to the possibility that 3DS' directors and officers may be placed in a conflict of interest as a result of their employment or affiliation with third parties, risks related to 3DS' use and storage of personal information and compliance with applicable privacy laws, as well as those risks discussed under the heading "Risk Factors" in the Company's annual management's discussion and analysis dated October 23, 2017 and filed on SEDAR. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the Forward-Looking Statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.
In making the Forward-Looking Statements, the Company has made various material assumptions including, but not limited to, 3DS' scoring model for its Telo-HLTM test, internal validation of TeloViewTM, peer-review and publication of its findings and establishing a new clinical paradigm for genome organization all being successful, obtaining positive results from 3DS' current and planned clinical studies and research and development initiatives; that the Telo-HLTM test will be commercially launched as an LDT or for research use by the first quarter of 2018; obtaining regulatory approvals with respect to 3DS' clinical studies which are now ongoing or may in the future be commenced; 3DS' ability to successfully develop its tests; assumptions regarding general business and economic conditions; that 3DS' current positive relationship with third parties will be maintained; the availability of future financing on reasonable terms; 3DS' ability to attract and retain skilled staff; assumptions regarding market competition and the products and technology offered by 3DS' competitors; and 3DS' ability to protect patents and proprietary rights.
3DS believes that the assumptions and expectations reflected in the Forward-Looking Statements in this press release are reasonable, but no assurance can be given that these expectations will prove to be correct. Forward-Looking Statements should not be unduly relied upon. This information speaks only as of the date of this press release, and 3DS will not necessarily update this information, unless required to do so by securities laws.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 3D Signatures Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Raising Internal Awareness About GDPR is Main Challenge, Say Subscription Businesses25.4.2018 20:00 | Pressmeddelande
WARRINGTON, United Kingdom, April 25, 2018 (GLOBE NEWSWIRE) -- With the countdown to the arrival of GDPR reaching the critical stages, more than a third of subscription businesses say that their biggest remaining challenge is raising internal awareness and knowledge about the legislation. GDPR comes into force May 25, with major implications for subscription businesses that collect personal data from B2B or B2C customers located in the EU. MPP Global hosted two recent webinars, focusing on the roles of data processor and data controller, to help businesses understand their responsibilities under the new regulations. Research conducted during these webinars uncovered that the main challenge identified by 34 percent of attendees ahead of GDPR was ensuring that their colleagues were aware of the changes in legislation and the potential implications of a breach. "These findings show that there is still some work to be done around GDPR," said MPP Global CEO and Co-Founder Paul Johnson. "GDP
PowerPlan Named Finalist for 2018 SAP® Pinnacle Award25.4.2018 16:10 | Pressmeddelande
ATLANTA, April 25, 2018 (GLOBE NEWSWIRE) -- PowerPlan is pleased to announce that SAP has recognized it as a finalist for an SAP® Pinnacle Award in the ISV Partner of the Year - Technology Innovation Award category. The annual SAP Pinnacle Awards acknowledge the contributions of leading SAP partners that have excelled in developing and growing their partnership with SAP and helping customers meet their goals. Finalists and winners in 29 categories were chosen based on recommendations from the SAP field, customer feedback and performance indicators. "We're honored to be recognized by SAP. Our distinction as a finalist highlights that the visions of PowerPlan and SAP continue to align," said Brent Burns, COO, PowerPlan. PowerPlan has been an OEM partner for SAP since June 2017. The introduction of the PowerPlan Adapter for SAP S4/HANA gained popularity due to its advanced cloud functionality and user-friendly interface. "Working with SAP has enabled our clients to run simple, yet strateg
Appian Announces 2018 Global and Regional Partners of the Year25.4.2018 15:01 | Pressmeddelande
RESTON, Va., April 25, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced its 2018 Global and Regional Partners of the Year winners. These strategic partners were selected based on their success in helping companies develop and execute digital transformation initiatives using Appian's low-code platform. Appian's partner ecosystem is consists of organizations that provide world-class solutions and services globally across a variety of industries. Global and Regional Partner of the Year Winners: Global Partner of the Year - KPMG Regional Partner of the Year, Europe - PwC Regional Partner of the Year, APAC - Incessant Regional Partner of the Year (Mid-Market) - Bits In Glass Global Trusted Program: Partner of the Year - Vuram "Our recognition as Appian's Global Partner of the Year for the third consecutive year demonstrates the strength of our combined business and technology leadership," said Jerry Iacouzzi, U.S. leader for digital enablement at KPMG. "Digital transformation i
LeoVegas kommentar på information gällande ändrade förutsättningar på den norska marknaden25.4.2018 14:32 | Pressmeddelande
I LeoVegas finansiella mål om intäkter på minst 600 MEUR år 2020 och minst 100 MEUR i EBITDA år 2020, som presenterades 19 april, har det tagits i beaktning att marknadsförutsättningar kan förändras. Meddelandet igår om förslaget till norska stortinget är ett exempel på ändrade förutsättningar som LeoVegas strategiska planering tagit höjd för. LeoVegas strävar efter att vara ett transparent bolag och väljer därför att ange storleken på den norska marknaden för att ge en ökad förståelse. I mars 2018 stod den norska marknaden för 4,6% av koncernens totala intäkter. Oavsett utgång påverkar utvecklingen i Norge inte LeoVegas finansiella mål. "Ännu finns det inga detaljer kring förslaget men i alla branscher får man räkna med att förutsättningarna kan ändras. Vissa marknader stängs ner och andra öppnas och regleras. Norge har idag inget lokalt licenssystem och istället för förbud hoppas jag att Norge rör sig mot en lokal reglering likt den utvecklingen vi ser i Sverige.", säger Gustaf Hagma
LeoVegas comments on information regarding the potential for changing circumstances in the Norwegian market25.4.2018 14:32 | Pressmeddelande
In LeoVegas financial targets of at least EUR 600 million in revenue in 2020 and at least EUR 100 million in EBITDA in 2020, that were presented on April 19th, it has been taken into account that market conditions can change. The announcement yesterday about the proposal in the Norwegian Parliament is an example of changing conditions that LeoVegas' strategic planning has made room for. LeoVegas strives to be a transparent company and therefore chooses to disclose the size of the Norwegian market in order to increase understanding of the potential impact. In March 2018, the Norwegian market accounted for 4.6% of LeoVegas total revenues. Regardless of the outcome the development in Norway, it does not affect LeoVegas financial targets. "There are still no details about the proposal, but in all industries, one can expect that the conditions can change. Some markets are closed and others are opened and regulated. Norway currently has no local licensing system, and instead of prohibition,
Gemini to Launch Market Surveillance Technology in Collaboration with Nasdaq25.4.2018 12:30 | Pressmeddelande
Nasdaq is providing SMARTS Market Surveillance technology to monitor cryptocurrency market NEW YORK and STOCKHOLM, Sweden, April 25, 2018 (GLOBE NEWSWIRE) -- Gemini Trust Company, LLC (Gemini) and Nasdaq Inc. (Nasdaq:NDAQ) announced today that Gemini will be leveraging Nasdaq's SMARTS Market Surveillance technology to monitor its marketplace. The technology, which is considered the most widely deployed surveillance system in the world, will enable Gemini to monitor across all of its trading pairs, including: BTC/USD, ETH/USD and BTC/ETH. Further, SMARTS will also surveil activity across the Gemini auction process that is used to determine the settlement price for the Bitcoin XBT futures contracts that trade on Cboe's CFE Exchange. "Since launch, Gemini has aggressively pursued comprehensive compliance and surveillance programs, which we believe betters our exchange and the cryptocurrency industry as a whole," said Tyler Winklevoss, CEO, Gemini. "Our deployment of Nasdaq's SMARTS Market
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum